Ranking of antiseizure medications in a panel of focal seizure models predicts their comparative efficacy in clinical add‐on trials in drug‐resistant focal epilepsy

The present study shows that ranking of ASMs across a panel of mechanistically complementary but agnostic models of focal-onset seizures yields greater translational accuracy and clinical predictivity for patients with focal DRE than rankings based on any single model. This novel finding can be used when defining a path forward that best identifies the most promising investigational compounds to advance to more expensive and time-consuming clinical investigations.